X-Chem | Evaluate

October 15, 2020

Clinical setback lays bare Vertex’s weakness

As the company is punished for its failure to diversify, could it be forced into making an acquisition?

June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data

Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

April 26, 2019

Astra’s first attempt fails, but there’s no giving up on KRAS

After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.

Evaluate

Clinical setback lays bare Vertex’s weakness

Asco 2019 – KRAS chase heats up with Amgen data

Astra’s first attempt fails, but there’s no giving up on KRAS

Latest Reports

H1 Round Up: The haves and the have-nots

ADA/EASL eBook

Editor's Picks

Astrazeneca and Daiichi’s big reveal disappoints

Pharma finds a way to gain weight

Protagonist investors flake as psoriasis pill disappoints

Approaching datasets for big pharma

Nkarta goes back to basics